BIOMATERIALS SUPPLIER PROTECTION PROVIDED IN SENATE PRODUCT LIABILITY BILL; MEASURE LACKS "FDA DEFENSE" LANGUAGE, NON-ECONOMIC DAMAGES CAP
This article was originally published in The Gray Sheet
Executive Summary
Biomaterials liability reform is included in the product liability bill passed by the Senate on May 10 in a 61-37 vote. The Senate bill, which had to have several contentious provisions removed before it passed, now must be reconciled with the broader liability reform bill passed by the House on March 10.